Summary
This prediction ended on 23.02.18 with a price of €14.72. The BUY prediction by melinda finished with a performance of 8.73%. melinda has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | 4.652% | 4.652% | -41.565% | -71.923% |
iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by melinda for this prediction
In the thread Evotec AG diskutieren
stoppen oder unten ganz Biotechnologie und medizinische SecteurRecherche
Startsignal? Evotec
Evotec engagiert in der Entdeckung und Entwicklung neuer Medikamente für die pharmazeutische und biotechnologische companies.It betreibt durch die EVT Execute und EVT Innovate Segmente EVT Execute Segment bietet Stand-alone oder integrierte Lösungen für die Wirkstoffforschung Ziele und Programme Collaborators